Toward Precision Longevity: Aging Interventions in the Single-Cell Atlas Era

Abstract

The authors review longevity interventions (genetic, dietary, exercise, pharmacological) studied in model organisms, arguing that single-cell sequencing technologies reveal cell-type-specific aging patterns previously masked by bulk analysis. They propose integrating single-cell atlas data with conventional interventions to design more precise, cellular-level anti-aging therapies.

Key Themes

1. Cellular heterogeneity — "Individual cell types in C. elegans age differently." Aging is not uniform across tissues.
2. Single-cell atlas as discovery platform — atlases identify the most aging-vulnerable cell populations and reveal conserved aging trajectories across species.
3. Limitations of systemic interventions — rapamycin benefits some tissues but impairs others (e.g., spermatogenesis). Whole-organism drugs have unavoidable tradeoffs.
4. Integration strategy — combining atlas findings with targeted delivery (LNPs, GalNAc, exosomes) enables precision interventions.
5. Cross-species conservation — mTOR, insulin/IGF signaling, FOXO genes are conserved from invertebrates to humans, enabling translation.

Interventions Reviewed

Genetic: insulin/IGF-1 suppression (daf-2/daf-16), mTOR inhibition, FOXO3 activation. Lifestyle: dietary restriction, exercise + myokines, polyphenols. Pharmacological: rapamycin/rapalogs, metformin, acarbose. Cellular: senolytics (dasatinib, quercetin), in vivo partial reprogramming (Yamanaka), blood-based rejuvenation (parabiosis, plasma exchange). Delivery: LNPs (mRNA), GalNAc conjugates, exosomes, viral vectors.

Atlas Resources Referenced

• C. elegans aging atlas (~47,000 somatic cells)
• Drosophila Aging Fly Cell Atlas (AFCA)
• Mouse aging atlases (PanSci, Tabula Muris Senis)

Open Questions / Research Gaps

1. Human atlas scarcity — "current scarcity of comparable human single-cell aging atlases" limits precision medicine translation.
2. Functional validation — does targeting adipose tissue slow systemic aging? Unresolved.
3. Temporal optimization — aging shows nonlinear acceleration at ages 44 and 60; optimal intervention timing remains undefined.
4. Pleiotropic effects — how to address multiple aging hallmarks within one cell type without off-target damage elsewhere.
5. Species-specific physiology — which aging trajectories in model organisms are evolutionarily conserved in humans?

Why This Review Matters

This is the bridge document between genetic/pharmacological longevity research and Life Biosciences–style cellular-reprogramming trials. It explains why single-eye injection might work where systemic dosing cannot — and identifies the human-atlas gap as the key bottleneck for scaling.

Source: Toward precision longevity: aging interventions in the single-cell atlas era, Chen, Wang, Gong, Li, Frontiers in Aging, Dec 5 2025.